Introduction
Paroxysmal nocturnal haemoglobinuria (PNH) is a rare and serious blood disorder that often appears in young adults and can stick around for a lifetime.1 It’s caused by a genetic failure in certain blood stem cells, leading to problems like haemolytic anaemia (where red blood cells break down too fast), dangerous blood clots, muscle issues, and sometimes even bone marrow failure. Without proper treatment, about half of the people with PNH face life-threatening complications from blood clots.2
There are treatment options for the disease, but the most complicated part is diagnosing it. However, diagnostic tools have become better at catching PNH early. It is important, since early detection is key to preventing serious issues like kidney damage or worsening blood problems.
In this article, you will learn the latest, most advanced tools doctors use to diagnose PNH.
Understanding PNH and the diagnostic challenge
In a healthy person, red blood cells (RBCs) are coated with protective proteins, like CD55 and CD59, which act like shields to keep the body’s immune system from attacking them. These proteins are fixed to the cell surface by a structure called glycosyl phosphatidylinositol (GPI). In PNH, the mutation disrupts this complex, so RBCs lack the protective proteins. Without them, the immune system mistakenly targets and destroys the unprotected RBCs. This leads to hemolytic anaemia, where RBCs break down too quickly, causing symptoms like fatigue, dark urine, and shortness of breath. The loss of these proteins also affects white blood cells and platelets, increasing the risk of blood clots and bone marrow failure.
Diagnosing PNH by symptoms and laboratory findings is challenging – symptoms of PNH are non-specific and can be present in any other disease. Symptoms include fatigue, shortness of breath, abdominal pain, headache, fever and dark urine.
Early diagnostic tools
Two tests were invented previously to detect PHN – the Ham test and the sucrose lysis (sugar water) test.
These tests checked how sensitive red blood cells were to the complement system (part of the immune system) by triggering hemolysis in a lab setting. The Ham test used acidified serum to see if RBCs would break down, and the sucrose lysis test used a sugar solution to activate complement.3 They were helpful back then, but had major flaws:
- They weren’t specific, meaning they could give false positives in other conditions that are not PHN
- They didn’t have high sensitivity, often missing small populations of PNH cells, especially in early stages or in patients with low RBC counts after transfusions or due to bone marrow issues
- They were time-consuming and depended on the timing of haemolysis, which could be irregular, leading to false negatives
These limitations made it hard to catch PNH early or accurately, delaying treatment and risking complications.
Modern diagnostic tools
Flow cytometry
The gold standard test for diagnosing PNH is called flow cytometry.1 It’s a high-tech way to analyse blood cells and spot the revealing signs of PNH. Flow cytometry uses lasers to scan blood samples and detect whether proteins like CD55 and CD59 are missing on RBCs, white blood cells, or platelets.
This test is highly accurate and can detect even small populations of PNH-affected cells (typically 1% or more). It is minimally invasive, requiring just a blood sample. Results usually come back quickly, helping doctors confirm PNH or rule it out without delay. Flow cytometry has become the core of PNH diagnosis because it’s reliable and can track the disease’s progression over time. The biggest advantages of this method are high sensitivity, reliability, and the ability to measure the size of the PNH clone. That is why flow cytometry replaced older tests.
High-sensitivity flow cytometry: catching PNH early
For some patients, PNH starts with only a tiny fraction of affected cells, which other tests might miss. High-sensitivity flow cytometry is an advanced version that can detect as few as 0.01% of PNH cells.4 This is especially helpful for catching PNH in its earliest stages or in people with related conditions, like aplastic anaemia, where PNH can develop as a secondary disease. By spotting the disease early, doctors can start monitoring or treating patients before symptoms get worse.
Fluorescent aerolysin (FLAER) testing
A newer, highly specific test for PNH uses a modified bacterial toxin called fluorescently labelled inactive aerolysin (FLAER).3 This molecule binds to the glycosyl phosphatidylinositol (GPI) complex – the structure missing in PNH cells – on a specific cell called granulocytes. Using flow cytometry, doctors detect the lack of the complex, which is a clear sign of PNH. FLAER is incredibly accurate and can detect PNH cells at levels as low as 0.5%, making it excellent for screening across different blood cell types in one test.
However, FLAER testing can be less reliable in patients with severe aplastic anaemia, where granulocyte counts are very low.
Imaging to detect complications
PNH increases the risk of blood clots (thrombosis), which can be life-threatening. Abdominal ultrasound, computed tomography (CT), or magnetic resonance imaging (MRI) may be used to evaluate venous thrombosis in patients with abdominal pain or headache or in cases of other venous thrombosis. These tests don’t diagnose PNH itself but are critical for finding complications.
Laboratory tests
PNH causes red blood cells to break down too quickly, a process called intravascular haemolysis,2 which can be confirmed by several blood tests:
- Lactate dehydrogenase (LDH): high levels indicate fast RBC destruction
- Reticulocyte count: elevated counts show the bone marrow is doing extra work to replace lost cells
- Haptoglobin: low or absent levels indicate hemolysis, especially if the liver and spleen are normal
- Haemoglobinuria and hemosiderinuria: These tests detect haemoglobin or haemosiderin (an iron-storage molecule) in the urine, one of the signs of PNH. However, haemolysis can be irregular, so these tests might not always catch it
Haemosiderin can also build up in the kidneys, visible on MRI or CT scans, which helps confirm PNH’s impact on the body.2 These tests don’t diagnose PNH but provide more information for a doctor’s decision-making.
Bone marrow analysis
In some cases, PNH affects the bone marrow’s ability to produce blood cells, leading to conditions like bone marrow failure.5 A bone marrow biopsy is a method, which a small sample is taken from the hip bone. It can help clarify whether PNH is the main issue or linked to another bone marrow disorder. During the course of PNH, the bone marrow activity could be different – in one phase, it is often overactive (hyperplastic), producing extra RBCs to compensate for their destruction; or it may be underactive (hypoplastic). Modern techniques, like immunohistochemistry, make this analysis more detailed, helping doctors understand the full scope of the disease. It is more invasive than a blood test, but this step is crucial for complex cases.
Genetic testing
Genetic testing, unlike flow cytometry, can detect problems at the DNA itself. PNH is caused by mutations in the PIGA gene, and advanced genetic tests, like next-generation sequencing (NGS), can identify these changes.3 This isn’t a routine test for everyone, but it’s very helpful in complex cases where doctors need to confirm the exact cause of symptoms or rule out other conditions. Genetic testing is usually done with blood, sometimes with bone marrow, too. And it gives doctors a better idea of what is happening inside the cells.
Future directions
Tests for PNH are getting better and more sensitive. One of the future directions is using artificial intelligence (AI) to help read flow cytometry more quickly and accurately. AI can check the data faster and sometimes see small details that people may not notice.6 This could help to find the disease earlier. Also, researchers are exploring less invasive ways to monitor PNH, like advanced imaging techniques or blood-based biomarkers that could reduce the need for bone marrow tests 7, so maybe in future, bone marrow tests will not be needed so often.
Conclusion
Diagnosing paroxysmal nocturnal hemoglobinuria has become easier in recent years as a result of new diagnostic tools like flow cytometry, genetic testing, and bone marrow analysis. These methods are more accurate and less invasive than previous tests, making it easier for doctors to catch PNH early and treat patients with it. For anyone experiencing symptoms like extreme fatigue, dark urine, or unexplained pain, talking to a doctor about these diagnostic options might be an important first step. Early detection and accurate monitoring are key to improving survival and quality of life for patients.
References
- Brando B, Gatti A, Preijers F. Flow Cytometric Diagnosis of Paroxysmal Nocturnal Hemoglobinuria: Pearls and Pitfalls – A Critical Review Article. EJIFCC 2019;30:355–70.
- Cançado RD, Araújo A da S, Sandes AF, Arrais C, Lobo CL de C, Figueiredo MS, et al. Consensus statement for diagnosis and treatment of paroxysmal nocturnal haemoglobinuria. Hematol Transfus Cell Ther 2021;43:341–8. https://doi.org/10.1016/j.htct.2020.06.006.
- Parker C. Diagnosis and management of paroxysmal nocturnal hemoglobinuria. Blood 2005;106:3699–709. https://doi.org/10.1182/blood-2005-04-1717.
- Guidelines for the diagnosis and monitoring of paroxysmal nocturnal hemoglobinuria and related disorders by flow cytometry. Read by QxMD n.d. https://read.qxmd.com/read/20533382/guidelines-for-the-diagnosis-and-monitoring-of-paroxysmal-nocturnal-hemoglobinuria-and-related-disorders-by-flow-cytometry (accessed September 18, 2025).
- Detection of paroxysmal nocturnal hemoglobinuria (PNH) in bone marrow aspirates ☆ . Read by QxMD n.d. https://read.qxmd.com/read/30573047/detection-of-paroxysmal-nocturnal-hemoglobinuria-pnh-in-bone-marrow-aspirates (accessed September 18, 2025).
- Worker A, Mahon H, Sams J, Boardman-Pretty F, Marchini E, Dubis R, et al. A machine learning algorithm for the detection of paroxysmal nocturnal haemoglobinuria (PNH) in UK primary care electronic health records. Orphanet Journal of Rare Diseases 2024;19:378. https://doi.org/10.1186/s13023-024-03406-4.
- Parker CJ. Update on the diagnosis and management of paroxysmal nocturnal hemoglobinuria. Haematology Am Soc Hematol Educ Program 2016;2016:208–16. https://doi.org/10.1182/asheducation-2016.1.208.

